Report cover image

Global OTC Anti-Infective Medications Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 198 Pages
SKU # APRC20362360

Description

Summary

According to APO Research, The global OTC Anti-Infective Medications market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for OTC Anti-Infective Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for OTC Anti-Infective Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for OTC Anti-Infective Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for OTC Anti-Infective Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of OTC Anti-Infective Medications include Abbott, Sanofi, Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, Optimer Pharmaceuticals and Novabay Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for OTC Anti-Infective Medications, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of OTC Anti-Infective Medications, also provides the revenue of main regions and countries. Of the upcoming market potential for OTC Anti-Infective Medications, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the OTC Anti-Infective Medications revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global OTC Anti-Infective Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for OTC Anti-Infective Medications revenue, projected growth trends, production technology, application and end-user industry.

OTC Anti-Infective Medications Segment by Company

Abbott
Sanofi
Novartis
Merck
Roche
Pfizer
GlaxoSmithKline
Optimer Pharmaceuticals
Novabay Pharmaceuticals
NanoViricides
MerLion Pharma
Bristol-Myers Squibb
Basilea Pharmaceutica
OTC Anti-Infective Medications Segment by Type

Antiseptic
Antiparasitics
Antifungals
OTC Anti-Infective Medications Segment by Application

E-Commerce
Drug Stores
Hospital Pharmacies
OTC Anti-Infective Medications Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of OTC Anti-Infective Medications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of OTC Anti-Infective Medications company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, OTC Anti-Infective Medications revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 OTC Anti-Infective Medications Market by Type
1.2.1 Global OTC Anti-Infective Medications Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antiseptic
1.2.3 Antiparasitics
1.2.4 Antifungals
1.3 OTC Anti-Infective Medications Market by Application
1.3.1 Global OTC Anti-Infective Medications Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 E-Commerce
1.3.3 Drug Stores
1.3.4 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 OTC Anti-Infective Medications Market Dynamics
2.1 OTC Anti-Infective Medications Industry Trends
2.2 OTC Anti-Infective Medications Industry Drivers
2.3 OTC Anti-Infective Medications Industry Opportunities and Challenges
2.4 OTC Anti-Infective Medications Industry Restraints
3 Global Growth Perspective
3.1 Global OTC Anti-Infective Medications Market Perspective (2020-2031)
3.2 Global OTC Anti-Infective Medications Growth Trends by Region
3.2.1 Global OTC Anti-Infective Medications Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global OTC Anti-Infective Medications Market Size by Region (2020-2025)
3.2.3 Global OTC Anti-Infective Medications Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global OTC Anti-Infective Medications Revenue by Players
4.1.1 Global OTC Anti-Infective Medications Revenue by Players (2020-2025)
4.1.2 Global OTC Anti-Infective Medications Revenue Market Share by Players (2020-2025)
4.1.3 Global OTC Anti-Infective Medications Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global OTC Anti-Infective Medications Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global OTC Anti-Infective Medications Key Players Headquarters & Area Served
4.4 Global OTC Anti-Infective Medications Players, Product Type & Application
4.5 Global OTC Anti-Infective Medications Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global OTC Anti-Infective Medications Market CR5 and HHI
4.6.3 2024 OTC Anti-Infective Medications Tier 1, Tier 2, and Tier 3
5 OTC Anti-Infective Medications Market Size by Type
5.1 Global OTC Anti-Infective Medications Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global OTC Anti-Infective Medications Revenue by Type (2020-2031)
5.3 Global OTC Anti-Infective Medications Revenue Market Share by Type (2020-2031)
6 OTC Anti-Infective Medications Market Size by Application
6.1 Global OTC Anti-Infective Medications Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global OTC Anti-Infective Medications Revenue by Application (2020-2031)
6.3 Global OTC Anti-Infective Medications Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Abbott
7.1.1 Abbott Comapny Information
7.1.2 Abbott Business Overview
7.1.3 Abbott OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.1.4 Abbott OTC Anti-Infective Medications Product Portfolio
7.1.5 Abbott Recent Developments
7.2 Sanofi
7.2.1 Sanofi Comapny Information
7.2.2 Sanofi Business Overview
7.2.3 Sanofi OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.2.4 Sanofi OTC Anti-Infective Medications Product Portfolio
7.2.5 Sanofi Recent Developments
7.3 Novartis
7.3.1 Novartis Comapny Information
7.3.2 Novartis Business Overview
7.3.3 Novartis OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.3.4 Novartis OTC Anti-Infective Medications Product Portfolio
7.3.5 Novartis Recent Developments
7.4 Merck
7.4.1 Merck Comapny Information
7.4.2 Merck Business Overview
7.4.3 Merck OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.4.4 Merck OTC Anti-Infective Medications Product Portfolio
7.4.5 Merck Recent Developments
7.5 Roche
7.5.1 Roche Comapny Information
7.5.2 Roche Business Overview
7.5.3 Roche OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.5.4 Roche OTC Anti-Infective Medications Product Portfolio
7.5.5 Roche Recent Developments
7.6 Pfizer
7.6.1 Pfizer Comapny Information
7.6.2 Pfizer Business Overview
7.6.3 Pfizer OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.6.4 Pfizer OTC Anti-Infective Medications Product Portfolio
7.6.5 Pfizer Recent Developments
7.7 GlaxoSmithKline
7.7.1 GlaxoSmithKline Comapny Information
7.7.2 GlaxoSmithKline Business Overview
7.7.3 GlaxoSmithKline OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.7.4 GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio
7.7.5 GlaxoSmithKline Recent Developments
7.8 Optimer Pharmaceuticals
7.8.1 Optimer Pharmaceuticals Comapny Information
7.8.2 Optimer Pharmaceuticals Business Overview
7.8.3 Optimer Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.8.4 Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
7.8.5 Optimer Pharmaceuticals Recent Developments
7.9 Novabay Pharmaceuticals
7.9.1 Novabay Pharmaceuticals Comapny Information
7.9.2 Novabay Pharmaceuticals Business Overview
7.9.3 Novabay Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.9.4 Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
7.9.5 Novabay Pharmaceuticals Recent Developments
7.10 NanoViricides
7.10.1 NanoViricides Comapny Information
7.10.2 NanoViricides Business Overview
7.10.3 NanoViricides OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.10.4 NanoViricides OTC Anti-Infective Medications Product Portfolio
7.10.5 NanoViricides Recent Developments
7.11 MerLion Pharma
7.11.1 MerLion Pharma Comapny Information
7.11.2 MerLion Pharma Business Overview
7.11.3 MerLion Pharma OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.11.4 MerLion Pharma OTC Anti-Infective Medications Product Portfolio
7.11.5 MerLion Pharma Recent Developments
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Comapny Information
7.12.2 Bristol-Myers Squibb Business Overview
7.12.3 Bristol-Myers Squibb OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.12.4 Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio
7.12.5 Bristol-Myers Squibb Recent Developments
7.13 Basilea Pharmaceutica
7.13.1 Basilea Pharmaceutica Comapny Information
7.13.2 Basilea Pharmaceutica Business Overview
7.13.3 Basilea Pharmaceutica OTC Anti-Infective Medications Revenue and Gross Margin (2020-2025)
7.13.4 Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio
7.13.5 Basilea Pharmaceutica Recent Developments
8 North America
8.1 North America OTC Anti-Infective Medications Revenue (2020-2031)
8.2 North America OTC Anti-Infective Medications Revenue by Type (2020-2031)
8.2.1 North America OTC Anti-Infective Medications Revenue by Type (2020-2025)
8.2.2 North America OTC Anti-Infective Medications Revenue by Type (2026-2031)
8.3 North America OTC Anti-Infective Medications Revenue Share by Type (2020-2031)
8.4 North America OTC Anti-Infective Medications Revenue by Application (2020-2031)
8.4.1 North America OTC Anti-Infective Medications Revenue by Application (2020-2025)
8.4.2 North America OTC Anti-Infective Medications Revenue by Application (2026-2031)
8.5 North America OTC Anti-Infective Medications Revenue Share by Application (2020-2031)
8.6 North America OTC Anti-Infective Medications Revenue by Country
8.6.1 North America OTC Anti-Infective Medications Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America OTC Anti-Infective Medications Revenue by Country (2020-2025)
8.6.3 North America OTC Anti-Infective Medications Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe OTC Anti-Infective Medications Revenue (2020-2031)
9.2 Europe OTC Anti-Infective Medications Revenue by Type (2020-2031)
9.2.1 Europe OTC Anti-Infective Medications Revenue by Type (2020-2025)
9.2.2 Europe OTC Anti-Infective Medications Revenue by Type (2026-2031)
9.3 Europe OTC Anti-Infective Medications Revenue Share by Type (2020-2031)
9.4 Europe OTC Anti-Infective Medications Revenue by Application (2020-2031)
9.4.1 Europe OTC Anti-Infective Medications Revenue by Application (2020-2025)
9.4.2 Europe OTC Anti-Infective Medications Revenue by Application (2026-2031)
9.5 Europe OTC Anti-Infective Medications Revenue Share by Application (2020-2031)
9.6 Europe OTC Anti-Infective Medications Revenue by Country
9.6.1 Europe OTC Anti-Infective Medications Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe OTC Anti-Infective Medications Revenue by Country (2020-2025)
9.6.3 Europe OTC Anti-Infective Medications Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China OTC Anti-Infective Medications Revenue (2020-2031)
10.2 China OTC Anti-Infective Medications Revenue by Type (2020-2031)
10.2.1 China OTC Anti-Infective Medications Revenue by Type (2020-2025)
10.2.2 China OTC Anti-Infective Medications Revenue by Type (2026-2031)
10.3 China OTC Anti-Infective Medications Revenue Share by Type (2020-2031)
10.4 China OTC Anti-Infective Medications Revenue by Application (2020-2031)
10.4.1 China OTC Anti-Infective Medications Revenue by Application (2020-2025)
10.4.2 China OTC Anti-Infective Medications Revenue by Application (2026-2031)
10.5 China OTC Anti-Infective Medications Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia OTC Anti-Infective Medications Revenue (2020-2031)
11.2 Asia OTC Anti-Infective Medications Revenue by Type (2020-2031)
11.2.1 Asia OTC Anti-Infective Medications Revenue by Type (2020-2025)
11.2.2 Asia OTC Anti-Infective Medications Revenue by Type (2026-2031)
11.3 Asia OTC Anti-Infective Medications Revenue Share by Type (2020-2031)
11.4 Asia OTC Anti-Infective Medications Revenue by Application (2020-2031)
11.4.1 Asia OTC Anti-Infective Medications Revenue by Application (2020-2025)
11.4.2 Asia OTC Anti-Infective Medications Revenue by Application (2026-2031)
11.5 Asia OTC Anti-Infective Medications Revenue Share by Application (2020-2031)
11.6 Asia OTC Anti-Infective Medications Revenue by Country
11.6.1 Asia OTC Anti-Infective Medications Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia OTC Anti-Infective Medications Revenue by Country (2020-2025)
11.6.3 Asia OTC Anti-Infective Medications Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA OTC Anti-Infective Medications Revenue (2020-2031)
12.2 SAMEA OTC Anti-Infective Medications Revenue by Type (2020-2031)
12.2.1 SAMEA OTC Anti-Infective Medications Revenue by Type (2020-2025)
12.2.2 SAMEA OTC Anti-Infective Medications Revenue by Type (2026-2031)
12.3 SAMEA OTC Anti-Infective Medications Revenue Share by Type (2020-2031)
12.4 SAMEA OTC Anti-Infective Medications Revenue by Application (2020-2031)
12.4.1 SAMEA OTC Anti-Infective Medications Revenue by Application (2020-2025)
12.4.2 SAMEA OTC Anti-Infective Medications Revenue by Application (2026-2031)
12.5 SAMEA OTC Anti-Infective Medications Revenue Share by Application (2020-2031)
12.6 SAMEA OTC Anti-Infective Medications Revenue by Country
12.6.1 SAMEA OTC Anti-Infective Medications Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA OTC Anti-Infective Medications Revenue by Country (2020-2025)
12.6.3 SAMEA OTC Anti-Infective Medications Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.